Crohn`s Disease (CD) Therapy - Global Strategic Business Report

The global market for Crohn's Disease (CD) Therapy was valued at US$13.3 Billion in 2024 and is projected to reach US$17.7 Billion by 2030, growing at a CAGR of 4.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Crohn's Disease (CD) Therapy Market - Key Trends and Drivers Summarized

Combating Crohn's Disease: What's New in CD Therapy?

Crohn's Disease (CD) therapy has evolved significantly, moving beyond traditional symptom management to more targeted approaches aimed at modifying the disease course and improving quality of life. Advances in medical research have led to the development of biologic therapies that specifically target proteins and pathways involved in inflammation. These include TNF inhibitors, integrin inhibitors, and interleukin inhibitors, which have shown efficacy in reducing symptoms and achieving remission in many patients. Additionally, the use of immunomodulators in combination with biologics has become a common strategy to enhance therapeutic outcomes and minimize side effects.

How Are Emerging Therapies Transforming Treatment Paradigms in CD?

Emerging therapies in CD focus on new targets within the immune system and the gut microbiome, which play crucial roles in the pathogenesis of the disease. JAK inhibitors, a newer class of small molecule drugs, have shown promise in treating moderate to severe CD by blocking key enzymes involved in the inflammatory process. Moreover, fecal microbiota transplantation (FMT) and the use of probiotics are being explored to restore intestinal microbiome balance, offering a novel approach to therapy that could potentially lead to better disease management and remission rates.

What Challenges Persist in the Management of Crohn's Disease?

Despite advancements, managing CD remains challenging due to its complex nature and variability in symptoms and treatment responses among patients. One of the biggest challenges is the chronic relapsing-remitting pattern of the disease, which can complicate long-term management strategies and affect patient adherence to treatment. Additionally, the risk of complications such as strictures, fistulas, and colorectal cancer requires ongoing monitoring and sometimes surgical intervention, adding to the disease burden. Furthermore, the cost of newer therapies, particularly biologics, can be prohibitively high, limiting access for many patients.

What Drives the Growth in the CD Therapy Market?

The growth in the CD therapy market is driven by several factors. An increasing incidence of inflammatory bowel diseases globally and greater awareness of CD are key factors contributing to the growing demand for effective treatments. Advances in diagnostic techniques allow for earlier and more accurate diagnosis, facilitating timely treatment initiation. The development of novel therapeutics that offer improved efficacy and safety profiles also stimulates market expansion. Additionally, rising healthcare expenditure and better healthcare infrastructure, particularly in developing countries, enhance access to advanced therapies, further driving market growth.

Report Scope

The report analyzes the Crohn's Disease (CD) Therapy market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments

Segment (Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars, Other Segments).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Anti-TNF Biologics segment, which is expected to reach US$7.4 Billion by 2030 with a CAGR of a 5.8%. The Aminosalicyates segment is also set to grow at 2.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $3.7 Billion in 2024, and China, forecasted to grow at an impressive 4.5% CAGR to reach $2.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as AbbVie, Inc., Amgen, Inc., AstraZeneca PLC, Biogen, Inc., Boehringer Ingelheim International GmbH and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Crohn's Disease (CD) Therapy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Crohn's Disease (CD) Therapy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Crohn's Disease (CD) Therapy Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Some of the 46 major companies featured in this Crohn's Disease (CD) Therapy market report include:

• AbbVie, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Celltrion Healthcare Co., Ltd.
• ChemoCentryx, Inc.
• Ferring Pharmaceuticals
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Novo Nordisk A/S
• Pfizer, Inc.
• Takeda Pharmaceutical Co., Ltd.
• UCB SA